NovelStem International Corp
NovelStem International Corp. (OTC Pink: NSTM) is a Boca Raton, Florida-based development-stage biotechnology holding company incorporated in 1993 and formerly known as Hollywood Media Corp. before its September 2018 name change, that holds a 30% equity stake in NewStem Ltd., an Israel-based biotechnology company developing stem cell-based diagnostic technology for cancer treatment optimization. NovelStem's strategic investment in NewStem gives it economic exposure to a potentially transformative technology platform that uses induced pluripotent stem cells (iPSCs) — stem cells derived from adult somatic cells through reprogramming — as the biological foundation for patient-specific cancer drug sensitivity testing.<br><br>NewStem's core technology applies iPSC-based methods to predict individual patients' resistance to specific chemotherapy regimens before treatment begins, enabling oncologists to select more effective, targeted treatment protocols and avoid the toxicity and treatment delays associated with administering chemotherapies to which a particular patient's tumor will not respond. The ability to predict chemotherapy resistance at the individual patient level represents a significant clinical advance in precision oncology, where the goal is to match each patient with the treatment most likely to be effective based on the unique biological characteristics of both the patient and their tumor. NewStem's platform is also being applied to genetic research for other medical conditions beyond oncology, expanding the potential scope of applications for its stem cell-based diagnostic capabilities.<br><br>NovelStem International Corp. became a fully SEC-reporting company following the automatic effectiveness of its Form 10 registration statement filed August 2, 2022, and subsequently secured a commitment for up to $600,000 in bridge funding to support its operations and investment in NewStem. The company trades on the OTC Pink market under the ticker symbol NSTM and files periodic reports with the Securities and Exchange Commission. As precision oncology continues to advance and the clinical and commercial value of predictive cancer diagnostics becomes better established, NovelStem's stake in NewStem Ltd. provides investors with indirect exposure to the development of stem cell-based diagnostic technology targeting the large and medically urgent global cancer treatment market.